Business
TREMFYA Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan
TREMFYA's market opportunities lie in its strong clinical efficacy, disease-modifying potential, and favorable safety profile across psoriasis and psoriatic arthritis. With broad label expansion into inflammatory conditions like IBD, its differentiated IL-23 inhibitor mechanism supports potential growth, especially in emerging markets.Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The "TREMFYA Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. The repo
About this update from Johnson & Johnson
[{"type":"image","alt":"Company Logo","displaySize":"","headline":null,"caption":"Company Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":36,"url":"https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LAb6sww2pvOwp1YOuMHMug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUw/https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65","width":300,"height":36},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/LAb6sww2pvOwp1YOuMHMug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUw/https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65","width":300,"height":36}},"lazy":false},{"type":"text","content":"TREMFYA's market opportunities lie in its strong clinical efficacy, disease-modifying potential, and favorable safety profile across psoriasis and psoriatic arthritis. With broad label expansion into inflammatory conditions like IBD, its differentiated IL-23 inhibitor mechanism supports potential growth, especially in emerging markets.","length":341,"tagName":"p"},{"type":"text","content":"Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The "TREMFYA Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering.","length":169,"tagName":"p"},{"type":"text","content":"The report delves into insights for TREMFYA across approved indications like Crohn's disease and potential areas such as hidradenitis suppurativa. Covering the 7MM regions, including the US, EU4, the UK, and Japan, the comprehensive report captures TREMFYA's historical and current market performance, developmental milestones, and emerging therapies that might influence its market stance.","length":398,"tagName":"p"},{"type":"text","content":"In February 2026, Johnson & Johnson unveiled new data from the QUASAR LTE study, affirming TREMFYA's sustained efficacy in ulcerative colitis through Week 140. These findings are showcased at the ECCO 2026 conference.","length":225,"tagName":"p"},{"type":"text","content":"TREMFYA Drug Summary","length":20,"tagName":"p"},{"type":"text","content":"TREMFYA, a human monoclonal antibody, targets the p19 subunit of IL-23, reducing pro-inflammatory T cell activation. Approved for psoriasis and psoriatic arthritis, it offers durable efficacy and a favorable safety pr...